arrow
L

Laura Marandino

the francis crick institute
H指数:30
被引数:3,169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

71 Integrated Spatial Multi-omics Reveals Tumour Immune Microenvironment Programmes Underlying Durable Response and Resistance to Dual ICI Therapy in ccRCC

71 整合空间多组学揭示ccRCC中持久应答和抗双ICI疗法下的肿瘤免疫微环境调控程序

2026-09-020
OAAI
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression

EMETPRO:一项多中心、国际性回顾性分析,评估早期进展的转移性激素敏感性前列腺癌患者

2026-05-290
PRE
HISTOPATHOLOGICAL OUTCOMES AFTER RENAL SURGERY: INSIGHTS FROM THE EAU-YAU RCC - US-KIDNET (UNITED STATES KIDNEY CANCER DATA NETWORK) COLLABORATIVE

肾手术后组织病理学结果:来自EAU-YAU RCC-US-KIDNET(美国肾癌数据网络)协作的见解

2026-05-010
PRE
Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials

同步转移性肾细胞癌中双免疫检查点抑制剂的长期真实世界生存结局:对前瞻性细胞减灭性肾切除术试验设计的启示

2025-12-190
OAAI
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions

肾细胞癌的新辅助和辅助免疫疗法:优势、劣势及未来方向

2024-09-010
OAAI
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
2024-05-011
OA
Diagnostic Biopsy for Small Renal Tumours: A Survey of Current European Practice
2024-04-016
OAAI
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy
2024-02-0111
OA